Official Title
National Prospective and Retrospective Follow-up of Patients With COVID-19 Infected Chronic Lymphocytic Leukemia / Lymphocytic Lymphoma or Waldenström Disease
Brief Summary

The COVID-19 epidemic (Coronavirus Disease 2019) which is currently raging in France is an emerging infectious disease linked to a virus of the genus coronavirus (SARS-CoV-2). The first cases were reported in Wuhan, China, in late December 2019 [1]. Globally, it has been placed in the "pandemic" stage by the WHO since March 11, 2020. Coronavirus viruses have been responsible for epidemics in the past such as the SARS epidemic in 2002 (Syndrome Severe Acute Respiratory) linked to the SARS-CoV virus, or the epidemic of MERS (Middle East Respiratory Syndrome) that affected the Middle East in 2012. Patients with chronic lymphocytic leukemia (CLL) / lymphocytic lymphoma or Waldenstrom Disease (WD) therefore represent a population at high risk of developing a severe form in the event of COVID-19 infection. To date, no data is available in the literature to assess the impact of the COVID-19 epidemic in this population of patients with CLL / lymphocytic lymphoma or WD.

Completed
Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma or Waldenstrom Disease

Behavioral: Data registry

Collection of clinical data, treatment regimens and survival data

Eligibility Criteria

Inclusion Criteria:

- Diagnosis of chronic lymphocytic leukemia / lymphocytic lymphoma or Waldenstrom
disease according to the criteria of the WHO 2016 with a proven or probable infection
by COVID-19 according to the following criteria:

- Proven infection: PCR positive regardless of the radio-clinical picture (Other tests
made available later and having good diagnostic performance will be accepted)

- Probable infection: the diagnosis of probable infection is retained in case of
negative PCR or not made if presence of at least 2 major criteria or of a major
criterion associated with at least 2 minor criteria among the following, in the
absence other documented cause.

- Major criteria:

- Fever

- Loss of smell / taste

- At least one respiratory sign among cough, dyspnea, chest pain

- Radiological signs suggestive of the scanner (areas or diffuse appearance of
frosted glass, condensations including pseudonodular condensations, association
of frosted glass and condensation within the same lesion, nodules and
micronodules, thickening of the interlobular septa) or on an X-ray of the thorax
( interstitial, alveolo-interstitial or alveolar syndrome, unilateral or
bilateral)

- Notion of storytelling with a person whose SARS-CoV-2 infection has been formally
documented

- Minor criteria

- Aches

- Sore throat

- Rhinorrhea

- Headache

- Diarrhea

- Abdominal pain

- Frank asthenia

- Conjunctivitis

Exclusion Criteria:

- Patient opposition

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
France
Locations

Chu Angers
Angers, France

CHU Jean Minjoz - Hématologie
Besançon, France

Hôpital Avicenne - Centre de Recherche Clinique
Bobigny, France

CHU Estaing - Hématologie Clinique Adulte
Clermont-Ferrand, France

Chu Creteil
Créteil, France

CHU Grenoble - Hématologie
Grenoble, France

Chd Vendee
La Roche-sur-Yon, France

Centre Hospitalier du Mans
Le Mans, France

Hôpital Saint Vicent de Paul
Lille, France

Centre Léon Bérard - Hématologie
Lyon, France

Institut Paoli Calmette
Marseille, France

Hopital E.Muller
Mulhouse, France

CHU DE NANTES - Hematologie clinique
Nantes, France

Hopital Pitie Salpetriere Service Hematologie Clinique - Pavillon de L'Enfant Et Adolescent
Paris, France

Centre Hospitalier Lyon Sud
Pierre-Bénite, France

Hôpital de la Milétrie - Hématologie et Thérapie Cellulaire
Poitiers, France

Hôpital Robert Debré - Hématologie Clinique
Reims, France

Centre Henri Becquerel - Service Hématologie Clinique
Rouen, France

Hôpital Hautepierre - Hématologie
Strasbourg, France

IUCT ONCOPOLE - Hématologie
Toulouse, France

Hôpital Bretonneau - Hématologie et Thérapie Cellulaire
Tours, France

CHU Nancy Brabois
Vandœuvre-lès-Nancy, France

Luc-Matthieu FORNECKER, Pr, Principal Investigator
French Innovative Leukemia Organisation

Institut de Cancerologie Strasbourg Europe
NCT Number
MeSH Terms
Lymphoma
Leukemia
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Osteochondritis